Vanguard Group’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-7,443,386
| Closed | -$145M | – | 4174 |
|
|
2018
Q1 | $145M | Buy |
7,443,386
+407,212
| +6% | +$7.99M | 0.01% | 1501 |
|
|
2017
Q4 | $117M | Buy |
7,036,174
+154,127
| +2% | +$2.83M | 0.01% | 1633 |
|
|
2017
Q3 | $140M | Buy |
6,882,047
+60,929
| +0.9% | +$1.16M | 0.01% | 1500 |
|
|
2017
Q2 | $110M | Buy |
6,821,118
+569,723
| +9% | +$8.42M | 0.01% | 1617 |
|
|
2017
Q1 | $79.1M | Buy |
6,251,395
+276,765
| +5% | +$3.34M | ﹤0.01% | 1779 |
|
|
2016
Q4 | $79.2M | Sell |
5,974,630
-105,247
| -2% | -$1.8M | ﹤0.01% | 1759 |
|
|
2016
Q3 | $144M | Buy |
6,079,877
+474,646
| +8% | +$12.8M | 0.01% | 1341 |
|
|
2016
Q2 | $162M | Buy |
5,605,231
+144,892
| +3% | +$4.72M | 0.01% | 1192 |
|
|
2016
Q1 | $175M | Buy |
5,460,339
+283,607
| +5% | +$9.97M | 0.01% | 1103 |
|
|
2015
Q4 | $221M | Buy |
5,176,732
+54,779
| +1% | +$2.19M | 0.01% | 944 |
|
|
2015
Q3 | $180M | Buy |
5,121,953
+198,137
| +4% | +$8.93M | 0.01% | 1052 |
|
|
2015
Q2 | $226M | Buy |
4,923,816
+119,109
| +2% | +$5.65M | 0.02% | 980 |
|
|
2015
Q1 | $225M | Buy |
4,804,707
+218,427
| +5% | +$8.69M | 0.02% | 970 |
|
|
2014
Q4 | $145M | Buy |
4,586,280
+100,224
| +2% | +$2.93M | 0.01% | 1163 |
|
|
2014
Q3 | $106M | Buy |
4,486,056
+83,492
| +2% | +$2.14M | 0.01% | 1308 |
|
|
2014
Q2 | $132M | Buy |
4,402,564
+732
| +0% | +$19.7K | 0.01% | 1218 |
|
|
2014
Q1 | $116M | Buy |
4,401,832
+168,037
| +4% | +$4.2M | 0.01% | 1258 |
|
|
2013
Q4 | $106M | Buy |
4,233,795
+184,910
| +5% | +$4.12M | 0.01% | 1281 |
|
|
2013
Q3 | $83M | Buy |
4,048,885
+97,745
| +2% | +$2.02M | 0.01% | 1368 |
|
|
2013
Q2 | $78.8M | Buy |
+3,951,140
| New | +$70.1M | 0.01% | 1323 |
|
Vanguard Group's IPXL Position: Q2 2018 in Review
Vanguard Group sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 7,443,386 shares — an estimated $145M sold.
Vanguard Group first reported a position in IPXL in Q2 2013 and held it in 20 quarters. The position peaked at $226M in Q2 2015. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Vanguard Group reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Vanguard Group sold 7,443,386 Impax Laboratories, Inc. shares in Q2 2018, an estimated $145M.
- Vanguard Group first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 20 quarters.
- Vanguard Group's Impax Laboratories, Inc. position peaked at $226M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Vanguard Group's 13F filing for Q2 2018, filed 14 Aug 2018.